Tempest Therapeutics Inc (NASDAQ:TPST) price on Friday, November 15, fall -8.27% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.89.
A look at the stock’s price movement, the close in the last trading session was $0.97, moving within a range at $0.8312 and $0.96. The beta value (5-Year monthly) was -2.776. Turning to its 52-week performance, $6.00 and $0.86 were the 52-week high and 52-week low respectively. Overall, TPST moved -22.62% over the past month.
Tempest Therapeutics Inc’s market cap currently stands at around $38.84 million, with investors looking forward to this quarter’s earnings report slated for on 2024-Nov-12.
Turning to the stock’s technical picture we see that short term indicators suggest on average that TPST is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 1 recommend TPST as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
TPST’s current price about -12.97% and -25.20% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 34.47, while 7-day volatility ratio is 10.39% and 9.14% in the 30-day chart. Further, Tempest Therapeutics Inc (TPST) has a beta value of -1.76, and an average true range (ATR) of 0.11.
If we refocus on Tempest Therapeutics Inc (NASDAQ:TPST), historical trading data shows that trading volumes averaged 2.42 over the past 10 days and 4.77 million over the past 3 months. The company’s latest data on shares outstanding shows there are 26.57 million shares.
The 15.13% of Tempest Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 9.27% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 2.64 million on 2024-10-31, giving us a short ratio of 0.39. The data shows that as of 2024-10-31 short interest in Tempest Therapeutics Inc (TPST) stood at 1262.0 of shares outstanding, with shares short rising to 1.86 million registered in 2024-09-30. Current price change has pushed the stock -79.77% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the TPST stock continues to rise going into the next quarter.
